Neuroscience | Novartis

Media Release
Apr 20, 2023
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Media Release
Jul 25, 2022
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Media Release
Sep 21, 2022
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Story
Oct 13, 2022
In neuroscience, “an inflection point in knowledge and technology”
Media Release
Jun 27, 2022
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Media Release
Jun 17, 2022
Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
Media Release
Apr 05, 2022
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Media Release
Jan 04, 2022
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
Media Release
Mar 02, 2022
Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta’s (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis
Media Release
Mar 08, 2022
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
Media Release
Mar 18, 2022
New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis
Media Release
Feb 16, 2021
Novartis Entresto® granted expanded indication in chronic heart failure by FDA